MARKET

CTSO

CTSO

Cytosorbents
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.420
+0.030
+0.89%
After Hours: 3.420 0 0.00% 16:01 01/19 EST
OPEN
3.410
PREV CLOSE
3.390
HIGH
3.470
LOW
3.272
VOLUME
322.58K
TURNOVER
--
52 WEEK HIGH
11.68
52 WEEK LOW
3.180
MARKET CAP
148.69M
P/E (TTM)
-9.3011
1D
5D
1M
3M
1Y
5Y
CytoSorbents Expects Upside FY21 Sales, Despite COVID-19 Headwinds
CytoSorbents Corp (NASDAQ: CTSO) reported preliminary 
Benzinga · 1d ago
CytoSorbents jumps 1.86% on prelim FY21 and Q4 revenue above the consensus
CytoSorbents (NASDAQ:CTSO) jumps 1.86% on preliminary FY21 unaudited total revenue of ~$43.2M (consensus $41.95M) versus $41M in 2020. Preliminary FY21 unaudited Product sales were ~$40.1M compared to $39.5M in 2020. Core (non-COVID-19) product
Seekingalpha · 1d ago
Do Insiders Own Lots Of Shares In Cytosorbents Corporation (NASDAQ:CTSO)?
If you want to know who really controls Cytosorbents Corporation ( NASDAQ:CTSO ), then you'll have to look at the...
Simply Wall St. · 01/12 09:57
BRIEF-Cytosorbents Entered Into Agreement With Jefferies Relating To Sale Of Shares Of Common Stock
reuters.com · 12/30/2021 22:31
Cytosorbents Granted U.S. Patent #11,202,855 ' Methods for removal of toxins from blood using an extracorporeal circuit comprised of a hollow-fiber filter module and polymer sorbent in combination'
View patent here
Benzinga · 12/21/2021 11:37
CytoSorbents Announced Publication of U.S. CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation in Frontiers in Medicine
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of resul...
Benzinga · 12/20/2021 12:11
28 Stocks Moving In Friday's Mid-Day Session
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor.
Benzinga · 12/17/2021 17:03
CytoSorbents Sponsored Study Titled 'CytOSorb TreatMent Of Critically Ill PatientS Registry' Posted To ClinicalTrials.gov; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05146336
Benzinga · 12/06/2021 15:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTSO. Analyze the recent business situations of Cytosorbents through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CTSO stock price target is 12.50 with a high estimate of 15.00 and a low estimate of 10.00.
High15.00
Average12.50
Low10.00
Current 3.420
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
    0
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 143
Institutional Holdings: 19.56M
% Owned: 44.98%
Shares Outstanding: 43.48M
TypeInstitutionsShares
Increased
32
1.18M
New
9
962.93K
Decreased
28
992.78K
Sold Out
15
306.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.17%
Healthcare Equipment & Supplies
-0.01%
Key Executives
Non-Executive Chairman/Independent Director
Al Kraus
President/Chief Operating Officer
Vincent Capponi
Chief Executive Officer/Director
Phillip Chan
Chief Financial Officer
Kathleen Bloch
Chief Scientific Officer
Efthymios Deliargyris
Independent Director
Michael Bator
Independent Director
Edward Jones
Independent Director
Alan Sobel
No Data
About CTSO
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is focused on investigating and commercializing blood purification technology to reduce uncontrolled inflammation in patients with focus in preventing or treating multiple organ failure. The Company's flagship product, CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb is used during and after cardiac surgery to remove inflammatory mediators, such as cytokines, activated compliment and free hemoglobin that can lead to post-operative complications, such as acute kidney injury, lung injury, shock, and stroke. Its purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Webull offers kinds of Cytosorbents Corp stock information, including NASDAQ:CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTSO stock methods without spending real money on the virtual paper trading platform.